Clinical Trial Update: Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive Disorder [Phase 3]

View source ↗

Summary

Wyeth, now a Pfizer subsidiary, completed a Phase 3 trial evaluating DVS-233 SR in adults with major depressive disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Depressive Disorder
• Major Depressive Disorder

Drugs mentioned

• DVS-233 SR

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Depression, Depressive Disorder | Phase 3 | Status: COMPLETED